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Abstract
Background: Strychnos potatorum Linn (Loganiaceae) is a moderate sized tree found in southern and central parts
of India, Sri Lanka and Burma. In traditional system of medicine, Strychnos potatorum Linn seeds were used for
various ailments including inflammation, diabetes etc. To investigate the folkloric use of the seeds the present
study was carried out on Freund’s adjuvant induced arthritic rats.
Methods: The present study states the effect of the aqueous extract (SPE) and the whole seed powder (SPP) of
Strychnos potatorum Linn seeds on the Freund’s complete adjuvant (FCA) induced arthritic rat paw edema, body
weight changes and alterations in haematological and biochemical parameters in both developing and developed
phases of arthritis. Histopathology of proximal interphalangeal joints and radiology of hind legs were studied.
Results: In FCA induced arthritic rats, there was significant increase in rat paw volume and decrease in body
weight increment, whereas SPP and SPE treated groups, showed significant reduction in paw volume and normal
gain in body weight. The altered haematological parameters (Hb, RBC, WBC and ESR) and biochemical parameters
(blood urea, serum creatinine, total proteins and acute phase proteins) in the arthritic rats were significantly
brought back to near normal by the SPP and SPE treatment at the dose of 200 mg/kg/p.o in both developing and
developed phases of arthritis. Further the histopathological and radiological studies revealed the antiarthritic
activity of SPP and SPE by indicating fewer abnormalities in these groups when compared to the arthritic control
group.
Conclusion: In conclusion, both SPP and SPE at the specified dose level of 200 mg/kg, p.o. showed reduction in
rat paw edema volume and it could significantly normalize the haematological and biochemical abnormalities in
adjuvant induced arthritic rats in both developing and developed phases of FCA induced arthritis. Further the
histopathological and radiological studies confirmed the antiarthritic activity of SPP and SPE.
Background
Rheumatoid arthritis (RA) is a systemic autoimmune
disease of unknown aetiology. The disease is character-
ized by articular inflammation and by the formation of
an inflammatory and invasive tissue, rheumatoid pannus
that eventually leads to the destruction of joints. Analge-
sia (painkillers) and anti-inflammatory drugs, including
steroids are used to suppress the symptoms, while dis-
ease-modifying antirheumatic drugs (DMARDs), newer
therapies such as anti-tumour necrosis factor (TNF)-a
therapy (etanercept, infliximab and adalimumab), anti-
CD20 therapy (rituximab) and abatacept are often
required to inhibit or halt the underlying immune pro-
cess. However, all of these agents are associated with
numerous side effects. In recent days, researchers are
directed towards traditional system of medicine for the
discovery of drugs that are long acting anti-inflamma-
tory with minimum side effects. Although there is no
ideal animal model for RA at this time, rat adjuvant
arthritis shares many features of human RA [1], and the
sensitivity of this model to antiarthritic agents [2] sup-
port the view the adjuvant arthritis is the best available
model of rheumatoid arthritis.
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moderate sized tree found in southern and central parts
of India, Sri Lanka and Burma [3]. The root cures all
kind of leucoderma. The ripe fruit is emetic, diaphoretic,
alexiteric, cures inflammation, anemia, jaundice [4]. The
seeds are used in hepatopathy, nephropathy, gonorrhoea,
leucorrhoea, gastropathy, bronchitis, chronic diarrhoea,
dysentery, renal and vesicle calculi, diabetes, burning sen-
sation, dipsia, conjunctivitis, scleritis, ulcers and other eye
diseases [5]. Phytochemical studies revealed the presence
of diaboline (major alkaloid) and its acetate [6], triter-
penes and sterols [7], mannogalactans [8]. The seeds are
reported to have various activities like antidiabetic [9],
antihypercholesterolemic activity [10], diuretic [11], anti-
diarrhoeal [12], hepatoprotective [13] and antiulcer [14].
Although the seeds possess many potential therapeutic
activities in traditional system of medicinal practice and
possessing rich phytoconstituents, they are not evaluated
for their pharmacological activities in detail. The other
species of the same genus, Strychnos nuxvomica was
used in the treatment of rheumatoid arthritis and it was
proved to be effective [15]. Taking these facts into con-
siderations, the present study deals with the evaluation
of antiarthritic activity and its changes in haematological
and biochemical parameters of the aqueous extract and
seed powder of Strychnos potatorum Linn seeds in
Freund’s adjuvant induced arthritic rats.
Methods
Collection of specimen (Strychnos potatorum Linn seeds)
The seed specimens for the proposed study were col-
lected from crude drug market, Chennai and the genui-
nity of the seed specimen was confirmed by Dr. S.
Jayaraman, Botanist, Plant Anatomy Research Centre,
Chennai, Tamilnadu. A voucher specimen has been
retained by the Department of Pharmacology and Envir-
onmental Toxicology (PET-02/2003), Dr.ALM PGIBMS,
University of Madras, Chennai.
Preparation of the extract
T h ea i r - d r i e ds e e d sw e r ec o a r s e l yp o w d e r e da n ds u b -
jected to hot water decoction for 2 hrs, it was then fil-
tered and the filtrate was evaporated to dryness. A grey
colored semisolid mass was obtained which was dried
under vacuum and kept in a desiccator. The percentage
yield of the extract (SPE) was 22.5% w/w from the start-
ing crude material. The seed powder (SPP) as such was
also used for the treatment. For the experimental study,
both the drugs (SPP and SPE) were triturated with dis-
tilled water and administered immediately.
Animals used
Wistar albino rats (140 ± 20 g) procured from TANU-
VAS (Tamilnadu University of Veterinary and Animal
Sciences) was used for the study. The animals were
kept in polypropylene cages and maintained at a tem-
perature of 22 ± 2°C. They were fed with standard pel-
let feed (TANUVAS) and water ad libitum.T h es t u d y
has got the approval from the Institutional Animal Ethi-
cal Committee (IAEC) of CPCSEA (Committee for the
Purpose of Control and Supervision of Experiments on
Animals).
Induction of arthritis
Arthritis was induced in rats by the intraplantar injec-
tion of 0.1 ml of Complete Freund’sA d j u v a n t( C F A )i n
the left hind paw [16]. The adjuvant contained heat
killed Mycobacterium tuberculosis (H37Rv strain, Tuber-
culosis Research Centre, ICMR, Chennai) in sterile par-
affin oil (10 mg/ml). The paw volume of all the animal
groups was measured by plethysmograph at 0, 7, 14, 21
and 28 days after the injection of Freund’sc o m p l e t e
adjuvant.
Experimental set up
Wistar albino rats of either sex weighing 140 ± 20 g
were used for the study. The animals were divided into
nine groups of six animals each. The standard drug
Diclofenac sodium is dissolved in water whereas SPP
and SPE were triturated with water in a glass mortar,
made as a suspension and administered immediately.
Group I served as control (without treatment), Group II
served as arthritic control (negative control), Group III
is treated with Diclofenac sodium (positive control) the
standard anti - arthritic drug, Group IV & VII were
treated with SPP and SPE for 28 days without inducing
arthritis, Group V and VIII received SPP and SPE treat-
ment for 28 days from the induction day (0-28 days
treatment). Groups VI and IX received SPP and SPE for
14 days from the 14
th day of induction (14
th to 28
th day
treatment). The body weight changes were observed on
every week.
On 29
th day, at the end of experiment, all animals
were sacrificed by cervical decapitation and blood was
collected in plain and EDTA containing tubes, respec-
tively for plasma/serum separation. The plasma/serum
and homogenized samples were subjected to biochem-
ical examination like total protein and albumin, globulin
[17], acute phase proteins- Fibrinogen [18] Ceruloplas-
min [19].
For histopathology, the proximal interphalangeal joints
were removed, washed with saline and stored in 10%
formalin. The interphalangeal joint sections were
obtained, stained with eosin-haematoxylin stain and
viewed under 100 X magnifications. The hind (arthritis
induced) legs of the experimental rats were taken X-ray,
and examined for the soft tissue swelling, bony erosions
and narrowing of the spaces between joints.
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The data represents Mean ± S.E.M. Results were ana-
lyzed statistically by One-Way ANOVA followed by
Tukey’s multiple comparison using SPSS software stu-
dent’s version. The difference was considered significant
when p < 0.05.
Results
FCA induced rat paw edema
There is a significant increase in rat paw volume in FCA
injected arthritic control rats when compared to the
normal control rats. SPP and SPE treatment at the dose
of 200 mg/kg showed significant reduction in rat paw
edema volume when compared with the arthritic group
(table 1).
Body weight changes
In the present study, it is clear from the data obtained
(Fig. 1), that there is a close relationship between the
extent of joint inflammation and the degree of weight
loss. In the first week after adjuvant injection, the
arthritic rats showed marked weight loss, followed by
normal weight gain in the subsequent weeks, whereas
the SPP, SPE and standard drug treated groups did not
show any weight loss.
Haematological parameters
The changes in hematological parameters in adjuvant
induced arthritic rats are shown in table 2. There was a
significant i) decrease in RBC count and haemoglobin,
ii) increase in WBC count and ESR of arthritic rats,
when compared with the control rats. The drug treat-
ment has significantly brought back the altered haema-
tological changes in both developing and developed
phases of adjuvant induced arthritis.
Blood glucose, urea and serum creatinine
Table 3 shows significant (p < 0.001) increase in the
values of blood urea and serum creatinine in adjuvant
induced arthritic rats when compared with the normal
control group. These alterations were significantly
reduced by treatment with SPP, SPE and Diclofenac
sodium.
Table 1 Effect of SPP and SPE on rat paw edema in Freund’s adjuvant induced arthritic rats
Rat paw volume in ml ± S.E.M (% inhibition)
Groups Day 0 Day 7 Day 14 Day 21 Day 28
Group I 0.22 ± 0.05 0.25 ± 0.09 0.21 ± 0.05 0.22 ± 0.09 0.21 ± 0.08
Group II 0.27 ± 0.03 0.82 ± 0.05 a* 0.80 ± 0.09 a* 0.71 ± 0.12 a* 0.77 ± 0.09 a*
Group III 0.26 ± 0.01
(0.037%)
0.53 ± 0.03 a*b*
(35.36%)
0.40 ± 0.05a* b*
(50%)
0.42 ± 0.05 a*b*
(40.84%)
0.38 ± 0.07 a
#b*
(50.64%)
Group IV 0.20 ± 0.07 0.23 ± 0.05 b* 0.25 ± 0.01 b* 0.26 ± 0.11 b* 0.22 ± 0.03b*
Group V 0.26 ± 0.06
(0.037%)
0.58 ± 0.04 a*b*
(29.26%)
0.48 ± 0.08 a*b*
(40%)
0.46 ± 0.09 a*b*
(35.21%)
0.42 ± 0.02 a*b*
(45.45%)
Group VI 0.24 ± 0.08
(11.11%)
0.62 ± 0.09 a*b*
(24.39%)
0.52 ± 0.09 a*b*
(35%)
0.52 ± 0.07 a*b*
(26.76%)
0.50 ± 0.04 a*b*
(35.06%)
Group VII 0.25 ± 0.04 0.25 ± 0.08 b* 0.26 ± 0.07 b* 0.26 ± 0.05 b* 0.21 ± 0.01b*
Group VIII 0.28 ± 0.09
(0.037%)
0.54 ± 0.05 a*b
# c
@
(34.14%)
0.50 ± 0.09 a*b* c
#
(37.5%)
0.49 ± 0.04 a*b*c
@
(30.98%)
0.45 ± 0.11 a*b*
(41.56%)
Group IX 0.24 ± 0.05
(11.11%)
0.67 ± 0.11 a*b*
(18.29%)
0.54 ± 0.08 a* b* c
@
(32.5%)
0.52 ± 0.08 a*b*
(26.76%)
0.52 ± 0.10 a*b*
(32.46%)
Values are Mean ± S.E.M, n = 6 animals in each group. Values in parenthesis indicate % inhibition of rat paw edema of treated groups Vs arthritic control group II.
Comparisons were made between: a- Group I vs II, III, IV, V, VI, VII, VIII and IX.
b- Group II vs III, IV, V, VI, VII, VIII and IX.
c- Group III vs V, VI, VIII and IX.
Symbols represent statistical significance: * - p < 0.001, # - p < 0.01, @ - p < 0.05.
Figure 1 Relationship between the extent of joint
inflammation and the degree of weight loss.
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The changes in total and individual protein levels are
presented in table 3. In adjuvant injected arthritic rats,
there was significant decrease (p < 0.001) in total pro-
tein, albumin levels and A/G ratio, but significant (p <
0.001) increase in globulin level on comparison with the
control group. On treatment with SPP, SPE and Diclofe-
nac sodium all these changes were brought back to
normal.
Acute phase proteins
Fibrinogen and ceruloplasmin are regarded as acute
phase proteins. In arthritis-induced rats, these two acute
phase markers were significantly (p < 0.001) increased
when compared with the arthritic control group (Table
3). Treatment with SPP and SPE have significantly (p <
0.001) decreased the levels of acute phase proteins in
arthritic rats.
Discussion
Paw swelling is an index of measuring the antiarthritic
activity of various drugs and it is employed here to
determine the activity of SPP and SPE at the dose level
200 mg/kg/p.o. SPP and SPE administered groups
showed marked reduction in paw volume when com-
pared with the arthritic control group. Yoshikawa et al.,
[20] found that there was significant weight loss, the day
following the injection of the adjuvant, but thereafter
continued to show normal weight gain in rats. The
result of the present study also indicates that there is a
close relationship between the extent of inflammation
and loss of body weight.
From the results it is clear that the decrease in RBC
count and haemoglobin level represents the anemic con-
dition in arthritic rats. The more important causes are
the abnormal storage of iron in the reticuloendothelial
system and synovial tissue and the failure of bone mar-
row to respond to anemia [21]. The significant increase
in leukocyte count in adjuvant-induced arthritic rats
may be due to the stimulation of immune system
against the invading antigens and the respective
decrease in SPP and SPE treated groups showed its
immunomodulation effect. The ESR count which signifi-
cantly increased in arthritic control group has been
remarkably counteracted by SPP, SPE and standard drug
Diclofenac sodium, restoring back to near normal thus
justifying its significant role in arthritic conditions.
Increased blood urea and serum creatinine level also
found in the arthritic control group which indicates the
kidney dysfunction in arthritic rats. SPP and SPE treat-
ment has significantly reduced the altered urea and
serum creatinine levels. Increased blood urea level was
reported in arthritic rats and it was hypothesized that
substantial fraction of blood urea in arthritic rats comes
from arginine synthesized in the kidneys [22].
In the present study there was a significant decrease in
albumin level and increase in globulin level in arthritic
rats. The adjuvant induced arthritis causes changes in
plasma protein concentrations that are manifested as an
increase in the globulin fraction and decrease in the
albumin fraction [23]. It was also postulated that during
inflammation, the mediators released, histamine, brady-
kinin and prostaglandins increase the permeability of
vascular tissues to albumin leading to reduction in its
serum levels [24]. Thus treatment with SPP and SPE
could significantly increase the albumin and decreased
the globulin level in arthritic rats which indicates that
SPP and SPE might have a suppressive action on the
mediators of inflammation.
The measurement of acute phase proteins in plasma
provides a clinically valuable indication of the presence
of inflammation and its extent [25]. Ceruloplasmin, a
Table 2 Effects of SPP and SPE on haematological parameters of control and adjuvant induced arthritic rats
Groups RBC (millions/mm
3) WBC (thousands/mm
3) Hb (g/dl) ESR (mm/hr)
Group I 5.84 ± 0.27 7.84 ± 0.34 14.22 ± 0.64 3.98 ± 0.07
Group II 4.95 ± 0.17 a* 12.94 ± 0.25 a* 11.54 ± 0.48 a* 10.56 ± 0.10 a*
Group III 5.78 ± 0.45 b* 8.75 ± 0.45 a
@b* 14.34 ± 0.58 b* 5.32 ± 0.08 a
#b*
Group IV 5.90 ± 0.18 b* 7.89 ± 0.34 b* 14.36 ± 0.64 b* 3.69 ± 0.14 b*
Group V 5.80 ± 0.14 b* 9.38 ± 0.48 a*b* 14.54 ± 0.27 b* 6.11 ± 0.16 a*b*
Group VI 5.79 ± 0.16 b* 10.65 ± 0.42 a*b*c
# 13.98 ± 0.34 b* 6.85 ± 0.08 a*b*
Group VII 6.01 ± 0.27 b* 7.57 ± 0.39 b* 14.33 ± 0.58 b* 3.09 ± 0.10 b*
Group VIII 5.87 ± 0.29 b* 8.96 ± 0.15 a
@b* 14.44 ± 0.34 b* 5.12 ± 0.14 a
#b*
Group IX 5.81 ± 0.21 b* 9.14 ± 0.81 a*b* 14.65 ± 0.45 b* 5.70 ± 0.09 a
#b*
Values are Mean ± S.E.M, n = 6 animals in each group.
Comparisons were made between: a- Group I vs II, III, IV, V, VI, VII, VIII and IX.
b- Group II vs III, IV, V, VI, VII, VIII and IX.
c- Group III vs V, VI, VIII and IX.
Symbols represent statistical significance: * - p < 0.001, # - p < 0.01, @ - p < 0.05.
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Page 4 of 9Table 3 Effects of SPP and SPE on Blood glucose, urea, creatinine and serum proteins of control and adjuvant induced arthritic rats
GROUPS Urea (mg/dl) Creatinine (mg/dl) Protein (g/dl) Albumin (g/dl) Globulin (g/dl) A/G ratio Cerruloplasmin (mg/dl) Fibrinogen (mg/dl)
Group I 22.64 ± 0.84 1.38 ± 0.06 6.62 ± 0.20 3.58 ± 0.06 2.30 ± 0.08 1.60 ± 0.10 19.65 ± 2.65 42.65 ± 2.28
Group II 30.54 ± 0.39 a* 2.38 ± 0.04 a* 4.28 ± 0.25 a* 2.36 ± 0.09 a* 2.86 ± 0.06 a* 0.79 ± 0.10 a* 52.74 ± 2.84 a* 162.45 ± 4.93 a*
Group III 23.15 ± 0.75 b* 1.67 ± 0.04 a
#b* 5.32 ± 0.18 a*b* 3.02 ± 0.10 a*b* 2.54 ± 0.04 a*b* 1.15 ± 0.08 a*b* 22.12 ± 1.34 b* 88.04 ± 3.22 a*b*
Group IV 21.64 ± 0.83 b* 1.42 ± 0.03 b* 6.59 ± 0.19 b* 3.54 ± 0.12 b* 2.22 ± 0.06 b* 1.60 ± 0.11 b* 18.54 ± 1.24 b* 43.68 ± 4.14 b*
Group V 24.45 ± 0.64 b
# 1.72 ± 0.08 a
#b* 5.30 ± 0.20 a*b* 2.98 ± 0.08 a*b* 2.58 ± 0.08 a*b* 1.18 ± 0.07 a*b* 26.81 ± 2.46 a
@b* 92.66 ± 5.64 a*b*
Group VI 25.88 ± 0.84 a
@b
# 1.79 ± 0.06 a*b* 5.24 ± 0.15 a*b* 2.89 ± 0.09 a*b* 2.62 ± 0.09 a*b* 1.12 ± 0.09 a*b* 26.24 ± 3.65 a
@b* 98.53 ± 6.82 a*b*
Group VII 21.16 ± 1.28 b* 1.33 ± 1.06 b* 6.52 ± 0.19 b* 3.64 ± 0.07 b* 2.24 ± 0.04 b* 1.61 ± 0.04 b* 18.63 ± 2.94 b* 42.20 ± 7.87 b*
Group VIII 23.27 ± 0.84 b* 1.65 ± 0.06 a
#b* 5.35 ± 0.16 a*b* 3.08 ± 0.06 a*b* 2.55 ± 0.06 a*b* 1.20 ± 0.08 a*b* 23.48 ± 2.45 b* 85.42 ± 8.60 a*b*
Group IX 24.84 ± 1.15 b
# 1.68 ± 0.08 a
#b* 5.30 ± 0.15 a*b* 2.97 ± 0.15 a*b* 2.58 ± 0.07 a*b* 1.18 ± 0.05 a*b* 24.35 ± 3.40 a
@b* 93.60 ± 5.40 a*b*
Values are Mean ± S.E.M, n = 6 animals in each group.
Comparisons were made between: a- Group I vs II, III, IV, V, VI, VII, VIII, IX.
b- Group II vs III, IV, V, VI, VII, VIII, IX.
c- Group III vs V, VI, VIII, IX.
Symbols represent statistical significance: * - p < 0.001, # - p < 0.01, @ - p < 0.05.
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9copper containing plasma protein is produced in liver in
response to tissue injury and released into circulation
[26]. Thus, its elevated serum level during chronic
arthritis might indicate continued tissue injury [27]. In
the present study, the increased acute phase proteins
fibrinogen and ceruloplasmin were significantly
decreased by the SPP and SPE treatment, which shows
its effect in tissue repair.
Figure 2 Histopathology of proximal interphalangeal joints on adjuvant induced arthritic rats.
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Page 6 of 9Figure 3 Radiology of hind legs in adjuvant induced arthritic rats.
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Page 7 of 9The observed histopathological changes of proximal
interphalangeal joints of the experimental groups are
shown in fig. 2. Group I showed the histopathology of
normal ankle joint. Group II the negative control
arthritic rat joint showed prominent abnormalities from
the normal joint like edema formation, degeneration
with partial erosion of the cartilage, destruction of bone
marrow and extensive infiltration of inflammatory exu-
dates in the articular surface. The standard drug treated
rat joint showed normal bone marrow with less cellular
infiltrates. SPP and SPE treatment for 28 days showed
less inflammatory signs like scanty cellular infiltrate,
absence of edema formation and normal bone marrow,
whereas the SPP and SPE treatment for 14 days showed
cellular infiltrates on the articular surface with less carti-
lage destruction. The overall prevention of the inflam-
matory signs of the rat ankle joints was significant in 28
days drug treated group compared with 14 days drug
treated group. Degeneration of the ankle joint was not
observed in any of the drug treated groups when com-
pared with the negative control.
Radiographic changes in RA conditions are useful
diagnostic measures which indicate the severity of the
disease. Soft tissue swelling is the earlier radiographic
sign, whereas prominent radiographic changes like bony
erosions and narrowing of joint spaces can be observed
only in the developed stages (final stages) of arthritis
[28]. The radiographic features of the rat joints in adju-
vant induced arthritic model are shown in fig. 2. In
adjuvant induced arthritic rat (group II), soft tissue swel-
ling along with narrowing of the joint spaces were
observed which implies the bony destruction in arthritic
condition. The standard drug Diclofenac sodium treated
groups have prevented this bony destruction and also
there is no swelling of the joint. Similar to histopatholo-
gical studies, SPP and SPE treatment for 28 days have
shown significant prevention against bony destruction
by showing less soft tissue swelling and narrowing of
joint spaces when compared with 14 days SPP and SPE
treated groups.
Conclusion
In conclusion, both SPP and SPE at the specified dose
level of 200 mg/kg, p.o. showed reduction in rat paw
edema volume and it could normalize the haematologi-
cal and biochemical abnormalities in adjuvant induced
arthritic rats in both developing and developed phases
of FCA induced arthritis. Further the histopathological
and radiological studies confirmed the antiarthritic
activity of SPP and SPE in FCA induced arthritis. The
actual mechanism of action of SPP and SPE on adjuvant
induced arthritis is not clear with these studies. The
action of SPP and SPE on proinflammatory mediators
like TNF- a, Interleukins and other relevant mediators
will be carried out in future to study its mechanism.
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